Table I.
CAPN6 expression and active pathways in tissues in different diseases.
| Disease | Effect | Active pathwaya | Refs. |
|---|---|---|---|
| Tumors | |||
| Uterine tumors | |||
| Uterine leiomyomas | Overexpression | Rac1/PAK1/CAPN6 | (26,49) |
| Uterine sarcoma | Overexpression | - | (40,50,52) |
| Cervical cancer | Overexpression | PI3K/AKT/CAPN6 | (12,51) |
| Osteosarcoma | Overexpression | EDN-1/ERK1/2, PI3K/AKT, NF-κB/CAPN6 | (27,41,60,61) |
| Liver cancer | Overexpression | PI3K/AKT/CAPN6 | (12,28,70) |
| Head and neck squamous cell carcinoma | Low expression | - | (42) |
| Neurological diseases | |||
| White matter injury | Low expression | miR-142-3p/miR-466b-5p/CAPN6 | (29) |
| Prion diseases | Overexpression | - | (43) |
| Vascular diseases | |||
| Atherosclerosis | Overexpression | CWC22/EJC/Rac1 | (46,78-80) |
| Target organ damage in hypertension | Low expression | - | (44) |
| Type 2 diabetic nephropathy | Overexpression | - | (45) |
| Muscular diseases | |||
| Muscular dystrophy | Overexpression | - | (21) |
| Muscular atrophy | Overexpression | - | (21) |
| Skin diseases | |||
| Atopic dermatitis | - | Key factors related to YWHAE | (47) |
a
Not all diseases involved have clear active pathways. CAPN6, calpain6; EDN-1, endothelin-1; NF-κB, nuclear factor-κ-gene binding; ERK1/2, extracellular regulated protein kinase 1/2; AKT, protein kinase B.